Based on these results, and other data suggesting that the IDH mutation may not be necessary for tumor maintenance in advanced phases of glioma progression [99,100,101], the use of IDH inhibitors is currently tested in earlier disease stages. This evidence concerns the gene IDH1 and central nervous system cancer.